Institutes For Biomed Novartis Buys 766,666 Shares of Novartis (NVS) Stock

Novartis (NYSE:NVS) major shareholder Institutes For Biomed Novartis acquired 766,666 shares of the stock in a transaction on Monday, April 23rd. The stock was bought at an average price of $15.00 per share, with a total value of $11,499,990.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

NVS opened at $76.99 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.91 and a current ratio of 1.17. Novartis has a 52-week low of $75.62 and a 52-week high of $94.19. The company has a market cap of $180,483.47, a PE ratio of 16.01, a price-to-earnings-growth ratio of 1.76 and a beta of 0.74.

How to Become a New Pot Stock Millionaire

Novartis (NYSE:NVS) last posted its earnings results on Thursday, April 19th. The company reported $1.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.03. Novartis had a return on equity of 16.23% and a net margin of 16.04%. The firm had revenue of $12.69 billion for the quarter, compared to analysts’ expectations of $12.45 billion. During the same period in the previous year, the firm earned $1.13 earnings per share. The business’s revenue was up 10.0% compared to the same quarter last year. equities analysts anticipate that Novartis will post 5.28 EPS for the current year.



Several analysts have weighed in on the company. JPMorgan Chase reiterated a “neutral” rating on shares of Novartis in a research report on Monday, April 9th. Nord/LB reiterated a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Deutsche Bank reiterated a “neutral” rating on shares of Novartis in a research report on Tuesday, April 10th. UBS reissued a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Finally, Zacks Investment Research cut Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. Novartis currently has an average rating of “Hold” and an average price target of $87.51.

Several institutional investors and hedge funds have recently bought and sold shares of NVS. Fisher Asset Management LLC grew its stake in Novartis by 2.8% in the fourth quarter. Fisher Asset Management LLC now owns 6,816,625 shares of the company’s stock worth $572,324,000 after purchasing an additional 183,641 shares during the period. BlackRock Inc. grew its stake in Novartis by 8.2% in the fourth quarter. BlackRock Inc. now owns 4,015,562 shares of the company’s stock worth $337,146,000 after purchasing an additional 305,221 shares during the period. Aristotle Capital Management LLC grew its stake in Novartis by 7.2% in the fourth quarter. Aristotle Capital Management LLC now owns 3,195,134 shares of the company’s stock worth $268,263,000 after purchasing an additional 215,584 shares during the period. Mawer Investment Management Ltd. grew its stake in Novartis by 3.5% in the fourth quarter. Mawer Investment Management Ltd. now owns 2,758,166 shares of the company’s stock worth $231,576,000 after purchasing an additional 92,908 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Novartis by 18.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,716,100 shares of the company’s stock worth $144,084,000 after purchasing an additional 271,900 shares during the period. 10.77% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Institutes For Biomed Novartis Buys 766,666 Shares of Novartis (NVS) Stock” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2018/04/25/institutes-for-biomed-novartis-buys-766666-shares-of-novartis-nvs-stock.html.

About Novartis

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply